The correlation between NfL reduction and clinical outcomes in ALS patients is a promising indicator. However, it's important to note that preclinical success doesn't always translate to clinical efficacy. The ongoing Phase 1 trial will be critical in establishing ATH-1105's safety profile and initial pharmacokinetics in humans. The timeline for ALS patient dosing in 2025 suggests a cautious but steady approach to development.